Rehmann Capital Advisory Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$262K	Buy	2,673 +366	+16%	+$41.3K	0.03%	272
2019 Q2	$302K	Buy	2,307 +14	+0.6%	+$1.8K	0.04%	351
2019 Q1	$310K	Buy	2,293 +588	+34%	+$73.1K	0.04%	321
2018 Q4	$166K	Sell	1,705 -1,228	-42%	-$145K	0.02%	284
2018 Q3	$408K	Buy	2,933 +283	+11%	+$35.5K	0.06%	245
2018 Q2	$329K	Sell	2,650 -73	-3%	-$8.53K	0.05%	274
2018 Q1	$304K	Buy	+2,723	New	+$325K	0.05%	276
2017 Q4	–	Sell	-1,719	Closed	-$241K	–	405
2017 Q3	$241K	Buy	+1,719	New	+$234K	0.04%	318
2016 Q1	–	Sell	-1,112	Closed	-$212K	–	398
2015 Q4	$212K	Buy	+1,112	New	+$194K	0.04%	310
2015 Q1	–	Sell	-1,081	Closed	-$200K	–	361
2014 Q4	$200K	Buy	+1,081	New	+$200K	0.05%	317

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rehmann Capital Advisory Group's ALXN Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its Alexion Pharmaceuticals (ALXN) stake by 16% in Q3 2019, buying an estimated $41.3K and bringing the position to 2,673 shares worth $262K. The position accounts for 0.03% of the portfolio, ranked #272.

Rehmann Capital Advisory Group first reported a position in ALXN in Q4 2014 and has held it in 10 quarters since. The position peaked at $408K in Q3 2018. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Rehmann Capital Advisory Group held 2,673 shares of Alexion Pharmaceuticals worth $262K as of Q3 2019.
Rehmann Capital Advisory Group bought 366 Alexion Pharmaceuticals shares in Q3 2019, an estimated $41.3K.
Alexion Pharmaceuticals made up 0.03% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #272 holding.
Rehmann Capital Advisory Group first reported a position in Alexion Pharmaceuticals in Q4 2014 and has held it in 10 quarters since.
Rehmann Capital Advisory Group's Alexion Pharmaceuticals position peaked at $408K in Q3 2018.
646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.